文献速递淋巴瘤

维布妥昔单抗联合苯达莫司汀治疗儿童复发/难治性霍奇金淋巴瘤

Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma.
PubMed 文献 · Blood Adv · 2021-01-01

66%患者达到完全代谢缓解,客观缓解率79%,3年无事件生存率和总生存率分别为65%和89%,耐受性良好。

要点

  • BVB方案在儿童复发/难治性霍奇金淋巴瘤中完全代谢缓解率达66%。
  • 3年无事件生存率和总生存率分别为65%和89%。
  • 主要毒性为血液学不良反应,3级输注反应发生率为10%。

核心结论

  • 对于儿童复发/难治性霍奇金淋巴瘤,BVB方案耐受性良好,且与目前可接受的挽救方案相比具有优势。

主要发现

  • 19例(66%)达到完全代谢缓解(95% CI,46-82)。
  • 23例(79%)观察到客观缓解(95% CI,60-92)。
  • 最常见的3级和4级毒性为血液学毒性,3例(10%)发生3级输注反应。
  • 18例中17例成功动员和采集干细胞;16例(13例自体,3例异基因)在BVB后接受巩固性移植。
  • BVB后3年无事件生存率为65%(95% CI,46-85),总生存率为89%(95% CI,74-100)。

关键数值与推荐

  • BVB方案:维布妥昔单抗1.8 mg/kg第1天输注,苯达莫司汀90 mg/m²第1天和第2天,每3周为一个周期。
  • 中位治疗周期数为3(范围2-7)。
  • 缓解评估依据Lugano分类标准,由当地放射科医生评估。

临床怎么用

  • BVB可作为儿童复发/难治性霍奇金淋巴瘤的挽救治疗选择,且不影响后续干细胞动员和采集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL), achieving a complete metabolic response (CMR) after salvage therapy is associated with superior outcomes, and optimal treatments must be identified. The combination of brentuximab vedotin and bendamustine (BVB), although highly active in adult patients, has not been extensively evaluated in pediatric patients with R/R HL. We performed a multicenter, retrospective review of pediatric patients <21 years of age with R/R HL treated with BVB from January 2016 through July 2019. Response was assessed by local radiologists according to Lugano classification criteria. Twenty-nine patients (17 relapsed, 12 refractory) with a median age of 16 years (range, 10-20) were treated with BVB and received a median of 3 cycles of therapy (range, 2-7). Patients received an infusion of 1.8 mg/kg of BV on day 1 with bendamustine 90 mg/m2 on days 1 and 2 of 3-week cycles. Nineteen patients (66%) achieved a CMR (95% CI, 46-82). An objective response was observed in 23 patients (objective response rate, 79%; 95% CI, 60-92). The most common grade 3 and 4 toxicities were hematologic, and 3 patients (10%) experienced grade 3 infusion reactions. Seventeen of 18 patients underwent successful mobilization and collection of stem cells. Sixteen patients (13 autologous, 3 allogeneic) received a consolidative transplant after BVB. The 3-year post-BVB event-free and overall survival were 65% (95% CI, 46-85) and 89% (95% CI, 74-100), respectively. For pediatric patients with R/R HL, BVB was well tolerated and compared favorably with currently accepted salvage regimens.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Forlenza CJ, Gulati N, Mauguen A, et al. Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma. Blood Adv. 2021. PMID: 34559223. doi:10.1182/bloodadvances.2021005268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。